Table 5:
Frequencies of Criteria for LR-M by Reader among HCC versus non-HCC Malignancies with Interrater Reliability Analysis
| Major Feature | HCC (n = 105) |
Non-HCC Malignancy (n = 73) |
p value* | Interpretation | K Value† | Agreement |
|---|---|---|---|---|---|---|
| Targetoid mass | … | … | … | … | 0.61 (0.49-0.72) | Substantial |
| R1 | 9 (9%) | 50 (68%) | <0.001 | More common among non-HCC | … | … |
| R2 | 25 (24%) | 63 (86%) | <0.001 | More common among non-HCC | … | … |
| Rim APHE | … | … | … | … | 0.55 (0.42-0.67) | Moderate |
| R1 | 5 (5%) | 40 (55%) | <0.001 | More common among non-HCC | … | … |
| R2 | 19 (18%) | 57 (78%) | <0.001 | More common among non-HCC | … | … |
| Peripheral “washout” | … | … | … | … | 0.05 (−0.36-0.47) | Slight |
| R1 | 1 (1%) | 13 (18%) | <0.001 | More common among non-HCC | … | … |
| R2 | 3 (3%) | 3 (4%) | 0.97 | No difference | … | … |
| Delayed central enhancement | … | … | … | … | 0.54 (0.39-0.69) | Moderate |
| R1 | 5 (5%) | 33 (45%) | <0.001 | More common among non-HCC | … | … |
| R2 | 11 (10%) | 37 (50%) | <0.001 | More common among non-HCC | … | … |
| Targetoid restriction | … | … | … | … | 0.34 (0.04-0.64) | Fair |
| R1 | 0 (0%) | 5 (7%) | 0.02 | No difference | … | … |
| R2 | 4 (4%) | 18 (25%) | <0.001 | More common among non-HCC | … | … |
| Targetoid TP or HBP appearance | … | … | … | … | 0.51 (0.16-0.87) | Moderate |
| R1 | 1 (1%) | 6 (8%) | 0.04 | No difference | … | … |
| R2 | 3 (3%) | 5 (7%) | 0.37 | No difference | … | … |
| Infiltrative appearance | … | … | … | … | 0.24 (−0.08-0.55) | Fair |
| R1 | 2 (2%) | 18 (25%) | <0.001 | More common among non-HCC | … | … |
| R2 | 0 (0%) | 8 (11%) | 0.002 | More common among non-HCC | … | … |
| Marked diffusion restriction | … | … | … | … | 0.05 (−0.29-0.38) | Slight |
| R1 | 0 (0%) | 2 (3%) | 0.33 | No difference | … | … |
| R2 | 6 (6%) | 19 (26%) | 0.002 | More common among non-HCC | … | … |
| Necrosis or severe ischemia | 0.07 (−0.36-0.51) | Slight | ||||
| R1 | 0 (0%) | 13 (18%) | <0.001 | More common among non-HCC | … | … |
| R2 | 3 (3%) | 2 (3%) | 1.00 | No difference | … | … |
*
p values are based on results from Pearson χ2 or Fisher exact test; p < 0.005 represents a significant difference.
†
Data in parentheses represent 95% confidence intervals.
Abbreviations: HCC – hepatocellular carcinoma; APHE – arterial phase hyperenhancement; HBP – hepatobiliary phase; LR-M – probably or definitely malignant but not HCC specific; R1 – reader 1; R2 – reader 2; TP – transitional phase